Added to YB: 2025-10-20
Pitch date: 2025-10-16
DRTS [bullish]
Alpha Tau Medical Ltd.
+28.5%
current return
Author Info
Anders Research shares equity research primarily focused on micro/small/mid-cap biotechnology. We follow companies with mechanistically differentiated approaches to large market opportunities, with special focus in neuroscience. Sign up for the newsletter.
Company Info
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.
Market Cap
$347.8M
Pitch Price
$3.93
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.99
P/E
-8.45
EV/Sales
N/A
Sector
Health Care Equipment and Supplies
Category
growth
Alpha Tau Medical: Localized Alpha Radiation, a New Paradigm in Oncology
DRTS: First localized alpha particle radiation therapy for solid tumors. 100% CR in cSCC (pivotal readout mid-2026), 100% ORR/50% CR in HNSCC combo w/ pembro, 97% DCR/19% ORR in pancreatic cancer despite only 20-55% tumor coverage. US pancreatic trial (30 pts) topline 3Q26. $340M mcap vs $8B+ radiopharm acquisitions.
Read full article (24 min)